InspireMD price target lowered to $4 from $4.50 at Piper Sandler

Piper Sandler lowered the firm’s price target on InspireMD (NSPR) to $4 from $4.50 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results with sales above its expectations. The company pushed out expectations for FDA approval for its CGuard Prime stent to Q3 2025 from the first half of 2025 due to circumstances beyond the company’s control. There was also a slight wiggle to expected U.S. launch timelines for the company’s SwitchGuard TCAR system in development to late 2026, Piper adds.